PE62396A1 - Derivado de indol - Google Patents

Derivado de indol

Info

Publication number
PE62396A1
PE62396A1 PE1996000145A PE00014596A PE62396A1 PE 62396 A1 PE62396 A1 PE 62396A1 PE 1996000145 A PE1996000145 A PE 1996000145A PE 00014596 A PE00014596 A PE 00014596A PE 62396 A1 PE62396 A1 PE 62396A1
Authority
PE
Peru
Prior art keywords
formula
alkyl
hydrogen
optionally substituted
group
Prior art date
Application number
PE1996000145A
Other languages
English (en)
Inventor
Fabio Romano Di
Nadia Conti
Magistris Elisabetta De
Aldo Feriani
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of PE62396A1 publication Critical patent/PE62396A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN DERIVADO DE INDOL DE FORMULA (I), O UNA SAL, O ESTER METABOLICAMENTE LABIL DEL MISMO, DONDE R ES SELECCIONADO DE HALOGENO, ALQUILO, ALCOXI, AMINO Y OTROS; m=0,1 o 2; A ES UN GRUPO ETINILO O ETENILO OPCIONALMENTE SUSTITUIDO, R1 ES HIDROGENO O UN GRUPO ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS; R2 ES HIDROGENO O ALQUILO, O R1 Y R2 JUNTO CON EL ATOMO DE NITROGENO AL CUAL ESTAN UNIDOS REPRESENTAN UN ANILLO HETEROCICLICO DE 5 A 7 MIEMBROS, EL CUAL PUEDE CONTENER UN HETEROATOMO ADICIONAL SELECCIONADO DE OXIGENO, AZUFRE O NITROGENO; R3 ES HIDROGENO O ALQUILO; n=0,1,2,3 o 4; X ES OXIGENO O AZUFRE; SE REFIERE ADEMAS AL PROCESO PARA PREPARAR EL COMPUESTO DE FORMULA (I), EN DONDE A ES UN GRUPO ETENILO OPCIONALMENTE SUSTITUIDO, QUE COMPRENDE LA REACCION DE UN COMPUESTO DE FORMULA (II) EN DONDE R1, R3, m Y n TIENEN EL SIGNIFICADO DE LA FORMULA (I), A ES UN GRUPO ETENILO OPCIONALMENTE SUSTITUIDO, R5 ES UN GRUPO PROTECTOR CARBOXILICO Y R6 ES HIDROGENO O UN GRUPO PROTECTOR DE NITROGENO, CON UN COMPUESTO DE LA FORMULA (III), DONDE X ES OXIGENO O AZUFRE, R1 Y R2 TIENEN EL MISMO SIGNIFICADO QUE EN LA FORMULA (I) Y R7 ES UN GRUPO FENOXI OPCIONALMENTE SUSTITUIDO, HALOGENO O IMIDAZOL. ES UTIL EN LA FABRICACION DE UN AGENTE TERAPEUTICO PARA ANTAGONIZAR LOS EFECTOS DE LOS AMINOACIDOS EXCITADORES SOBRE EL COMPLEJO DEL RECEPTOR NMDA
PE1996000145A 1995-03-04 1996-03-01 Derivado de indol PE62396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9504361.8A GB9504361D0 (en) 1995-03-04 1995-03-04 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
PE62396A1 true PE62396A1 (es) 1997-01-11

Family

ID=10770638

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000145A PE62396A1 (es) 1995-03-04 1996-03-01 Derivado de indol

Country Status (23)

Country Link
US (1) US5919811A (es)
EP (1) EP0813524A1 (es)
JP (1) JPH11501041A (es)
KR (1) KR19980702735A (es)
CN (1) CN1182417A (es)
AR (1) AR002711A1 (es)
AU (1) AU708291B2 (es)
BR (1) BR9607346A (es)
CA (1) CA2214583A1 (es)
CO (1) CO4700452A1 (es)
CZ (1) CZ277997A3 (es)
EA (1) EA000308B1 (es)
GB (1) GB9504361D0 (es)
HU (1) HUP9801838A3 (es)
IL (1) IL117331A (es)
MX (1) MX9706605A (es)
NO (1) NO309323B1 (es)
NZ (1) NZ303200A (es)
PE (1) PE62396A1 (es)
PL (1) PL322084A1 (es)
TW (1) TW438773B (es)
WO (1) WO1996027588A1 (es)
ZA (1) ZA961697B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
JP2005518371A (ja) * 2001-12-10 2005-06-23 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療に於けるこれらの使用
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
ATE552236T1 (de) * 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
ES2419007T3 (es) * 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
EP1959947A2 (en) * 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
WO2009035927A2 (en) * 2007-09-13 2009-03-19 Arete Therapeutics, Inc. Bis-cyclyl substitued ureas or amides as soluble epoxide hydrolase inhibitors
PE20091101A1 (es) 2007-12-18 2009-07-26 Pharminox Ltd AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO
ES2583006T3 (es) 2009-06-23 2016-09-16 Pharminox Limited Compuestos de 3-sustituido-8-sustituido-3H-imidazo[5,1-d][1,2,3,5-tetrazin-4-ona y su uso
US20130012706A1 (en) 2010-03-01 2013-01-10 Pharminox Limited Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines
WO2012085501A1 (en) 2010-12-20 2012-06-28 Pharminox Limited 8 - sulfo - imidazotetrazin- 4 - one compounds and their use as anticancer drug
TWI882026B (zh) 2019-11-11 2025-05-01 荷蘭商卡普三世責任有限公司 工業規模上用於生產ε-己內醯胺及硫酸銨之方法及設備

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
IL117331A (en) 2000-06-29
GB9504361D0 (en) 1995-04-26
EP0813524A1 (en) 1997-12-29
NO974043D0 (no) 1997-09-03
CA2214583A1 (en) 1996-09-12
CZ277997A3 (cs) 1998-06-17
HUP9801838A2 (hu) 1998-12-28
TW438773B (en) 2001-06-07
EA199700160A1 (ru) 1998-02-26
AU4943896A (en) 1996-09-23
NO309323B1 (no) 2001-01-15
CN1182417A (zh) 1998-05-20
BR9607346A (pt) 1997-12-30
PL322084A1 (en) 1998-01-05
IL117331A0 (en) 1996-07-23
JPH11501041A (ja) 1999-01-26
WO1996027588A1 (en) 1996-09-12
US5919811A (en) 1999-07-06
AR002711A1 (es) 1998-04-29
EA000308B1 (ru) 1999-04-29
AU708291B2 (en) 1999-07-29
KR19980702735A (ko) 1998-08-05
MX9706605A (es) 1998-02-28
HUP9801838A3 (en) 2000-04-28
CO4700452A1 (es) 1998-12-29
ZA961697B (en) 1997-10-01
NO974043L (no) 1997-11-03
NZ303200A (en) 1999-01-28

Similar Documents

Publication Publication Date Title
PE62396A1 (es) Derivado de indol
ES8404327A1 (es) Un procedimiento para la preparacion de un derivado del indol.
ES8305678A1 (es) "un procedimiento para prepara derivados de fenilciclobutano".
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
TR200100439T2 (tr) 1H-İmidazopiridin türevleri
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
ES8600305A1 (es) Procedimiento de preparar compuestos beta-lactamicos
DE69522676D1 (de) Naphtalen-derivate als prostaglandin i2 agonisten
DE3854454D1 (de) Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung.
PL369232A1 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
PE49696A1 (es) Compuesto carbociclico
ES2065755T3 (es) Derivados de 3-aminopiridacinas activos sobre el sistema nervioso central.
CA2178604A1 (en) Novel imidazole derivative and process for producing the same
DE69323712D1 (de) Indol derivate zur behandlung von migräne
ES8603497A1 (es) Procedimiento para preparar derivados de cefalosporina
MX9201556A (es) Nuevos antihistaminicos no sedativos, derivados de benc imidazoles.
ES2011919A6 (es) Metodo para producir compuestos antagonistas de los leucotrienos.
ES2136291T3 (es) Derivados de pirimidina.
DE69332945D1 (de) Indol-derivat, verfahren zu dessen herstellung und dessen medizinische anwendung
CO4970744A1 (es) Caspasas y apoptosis
AR006719A1 (es) Derivados de bencilamina y formulacion farmaceutica que comprende a uno de dichos derivados.
ES8505966A1 (es) Un procedimiento para la preparacion de compuestos de bencimidazol
NO20000737L (no) Tetrahydro <gamma>-karboliner
DK0888337T3 (da) Piperidon-tachykininantagonister
CO4290299A1 (es) Derivados de 1,5-benzodiazepina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed